Astrazeneca (AZN) Finished Goods (2015 - 2025)

Astrazeneca (AZN) has reported Finished Goods for 11 consecutive years, with $1.9 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Finished Goods rose 26.76% year-over-year to $1.9 billion; the TTM figure through Dec 2025 stood at $1.9 billion (up 26.76% YoY), while the FY2025 annual figure was $1.9 billion, up 26.76% from the prior year.
• Finished Goods came in at $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• The five-year high for Finished Goods was $2.0 billion in Q4 2021, with the low at $1.4 billion in Q4 2022.
• Average Finished Goods over 5 years is $1.7 billion, with a median of $1.6 billion recorded in 2023.
• Across the five-year window, Finished Goods surged 40.6% in 2021 and decreased 29.77% in 2022, its largest moves.
• Year by year, Finished Goods stood at $2.0 billion in 2021, then retreated by 29.77% to $1.4 billion in 2022, then gained by 10.97% to $1.6 billion in 2023, then fell by 3.25% to $1.5 billion in 2024, then climbed by 26.76% to $1.9 billion in 2025.
• According to Business Quant data, Finished Goods over the past three periods registered $1.9 billion, $1.5 billion, and $1.6 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.